Cargando…

Extended adjuvant endocrine therapy in a longitudinal cohort of young breast cancer survivors

Extended adjuvant endocrine therapy (eET) improves outcomes in breast cancer survivors. Most studies however have been limited to postmenopausal women, and optimal eET for young survivors is uncertain. We report eET use among participants in the Young Women’s Breast Cancer Study (YWS), a multicenter...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sella, Tal, Zheng, Yue, Rosenberg, Shoshana M., Ruddy, Kathryn J., Gelber, Shari I., Tamimi, Rulla M., Peppercorn, Jeffrey M., Schapira, Lidia, Borges, Virginia F., Come, Steven E., Carey, Lisa A., Winer, Eric P., Partridge, Ann H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130172/ https://www.ncbi.nlm.nih.gov/pubmed/37185922 http://dx.doi.org/10.1038/s41523-023-00529-y

Ejemplares similares

Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer
por: Poorvu, Philip D., et al.
Publicado: (2020)

Treatment-related amenorrhea in a modern, prospective cohort study of young women with breast cancer
por: Poorvu, Philip D., et al.
Publicado: (2021)

Patient perspectives on testing for clonal hematopoiesis of indeterminate potential
por: Sella, Tal, et al.
Publicado: (2022)

Somatic and Germline Genomic Alterations in Very Young Women with Breast Cancer
por: Waks, Adrienne G., et al.
Publicado: (2022)

Prospective evaluation of the impact of stress, anxiety, and depression on household income among young women with early breast cancer from the Young and Strong trial
por: Cook, Erin E., et al.
Publicado: (2020)

Evaluation of significant genome-wide association studies risk — SNPs in young breast cancer patients
por: Rath, Michelle, et al.
Publicado: (2019)

Correction: Evaluation of significant genome-wide association studies risk—SNPs in young breast cancer patients
por: Rath, Michelle, et al.
Publicado: (2020)

Understanding adjuvant endocrine therapy persistence in breast Cancer survivors
por: Lambert, Leah K., et al.
Publicado: (2018)

Psychosocial needs of young breast cancer survivors in Mexico City, Mexico
por: Hubbeling, Harper G., et al.
Publicado: (2018)

An unmet need: tailoring extended adjuvant endocrine therapy
por: Bianchini, G, et al.
Publicado: (2013)

Contemporary multidisciplinary treatment of pregnancy-associated breast cancer
por: Meisel, Jane L, et al.
Publicado: (2013)

Single nucleotide polymorphisms and breast cancer: not yet a success story
por: Tamimi, Rulla M
Publicado: (2006)

Potentially Modifiable Factors Associated with Adherence to Adjuvant Endocrine Therapy among Breast Cancer Survivors: A Systematic Review
por: Toivonen, Kirsti I., et al.
Publicado: (2020)

Increased risk of breast cancer-specific mortality among cancer survivors who developed breast cancer as a second malignancy
por: Wang, Chengshi, et al.
Publicado: (2021)

Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer
por: van Hellemond, Irene E. G., et al.
Publicado: (2018)

Health belief about adjuvant endocrine therapy in premenopausal breast cancer survivors: a qualitative study
por: Xu, Lei, et al.
Publicado: (2019)

Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic
por: Park, Ko Un, et al.
Publicado: (2021)

Study protocol for a randomised controlled feasibility trial of a virtual intervention (STRIDE) for symptom management, distress and adherence to adjuvant endocrine therapy after breast cancer
por: Jacobs, Jamie M, et al.
Publicado: (2021)

Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer. A systematic review and meta-analysis of randomized clinical trials()
por: Pala, Laura, et al.
Publicado: (2023)

Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review
por: Matthews, Anthony, et al.
Publicado: (2018)

Impact of patient race and geographical factors on initiation and adherence to adjuvant endocrine therapy in medicare breast cancer survivors
por: Camacho, Fabian T., et al.
Publicado: (2017)

The relationship between work-related outcomes and symptoms in early breast cancer survivors receiving adjuvant endocrine therapy
por: Nakao, Mayumi, et al.
Publicado: (2022)

Adherence to adjuvant endocrine therapy among White British and ethnic minority breast cancer survivors in the United Kingdom
por: McGuinness, Serena, et al.
Publicado: (2022)

Endocrine complications in survivors of childhood medulloblastoma
por: Yuet-ling, Joanna Tung, et al.
Publicado: (2015)

Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests
por: Saponaro, Mariarosaria, et al.
Publicado: (2022)

Extended Adjuvant Endocrine Therapy in Early Breast Cancer Patients—Review and Perspectives
por: Bekes, Inga, et al.
Publicado: (2023)

Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer
por: Ribi, K, et al.
Publicado: (2012)

Systematic adaptation of the adherence improving self‐management strategy to support breast cancer survivors' adherence to adjuvant endocrine therapy: An intervention mapping approach
por: Janssen, Anna M., et al.
Publicado: (2022)

Improved adjuvant endocrine therapy for premenopausal women with endocrine responsive disease
por: Goldhirsch, Aron, et al.
Publicado: (2015)

Hobson’s choice or a horned dilemma: a grounded theory on adherence to adjuvant endocrine therapy verified with breast cancer survivors
por: AlOmeir, Othman, et al.
Publicado: (2022)

Endocrine Late Effects in Childhood Cancer Survivors
por: Casano-Sancho, Paula, et al.
Publicado: (2022)

Interpreting breast international group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer
por: Regan, Meredith M, et al.
Publicado: (2011)

Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT
por: Pagani, Olivia, et al.
Publicado: (2020)

Strategies to self-manage side-effects of adjuvant endocrine therapy among breast cancer survivors: an umbrella review of empirical evidence and clinical guidelines
por: Hall, Louise H., et al.
Publicado: (2021)

Quality of Life Following Receipt of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node–Positive and High-Risk Lymph Node–Negative Breast Cancer
por: Rosenberg, Shoshana M., et al.
Publicado: (2022)

Status of adjuvant endocrine therapy for breast cancer
por: Schiavon, Gaia, et al.
Publicado: (2014)

Positive effect of tamoxifen as part of adjuvant chemo-endocrine therapy for breast cancer. Hokkaido Adjuvant Chemo-Endocrine Therapy for Breast Cancer Study Group.
por: Uchino, J., et al.
Publicado: (1994)

Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practice
por: Buono, Giuseppe, et al.
Publicado: (2022)

The Effects of Pharmacological and Non-Pharmacological Interventions on Symptom Management and Quality of Life among Breast Cancer Survivors Undergoing Adjuvant Endocrine Therapy: A Systematic Review
por: Chan, Carmen W.H., et al.
Publicado: (2020)

The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS)
por: Hwang, E Shelley, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_h50rhfpl1pe8hpuekos9ihk9t2